Search Results
Your search for AT matches 29280 pages
Showing 6151 - 6200Can AI Assist in Predicting Spinal Fractures in Patients With Cancer?
A new study published by Ahmadian et al in the International Journal for Numerical Methods in Biomedical Engineering suggests how scientists may use artificial intelligence (AI) to predict how cancer may affect the probability of fractures along the spinal column. The report described how the...
Consolidation Durvalumab Alone or Combined With Oleclumab or Monalizumab for Unresectable Stage III NSCLC
In an interim analysis of the phase II COAST trial reported in the Journal of Clinical Oncology, Roy S. Herbst, MD, PhD, FACP, FASCO, and colleagues found that consolidation durvalumab in combination with the anti-CD73 antibody oleclumab or anti-NKG2A antibody monalizumab both improved objective...
Lenvatinib/Pembrolizumab vs Sunitinib in Patients With Advanced Renal Cell Carcinoma: Health-Related Quality-of-Life Outcomes
In a study reported in The Lancet Oncology, Robert Motzer, MD, and colleagues found that patients with previously untreated advanced renal cell carcinoma receiving lenvatinib/pembrolizumab had similar or favorable health-related quality of life scores and prolonged time to definitive deterioration...
Segmentectomy vs Lobectomy in Small-Sized Peripheral NSCLC
In a Japanese phase III trial (JCOG0802/WJOG4607L) reported in The Lancet, Saji et al found that segmentectomy was both noninferior and superior to lobectomy as measured by overall survival in patients with small-sized peripheral non–small cell lung cancer (NSCLC). Study Details In the open-label...
FDA Grants Regular Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Breast Cancer
On May 4, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu) for pretreated adult patients with unresectable or metastatic HER2-positive breast cancer. According to the approval, patients had to have received a prior anti-HER2–based regimen either in the...
Study Examines Link Between Emphysema and Lung Cancer Risk
Computed tomography (CT)-detected emphysema may be linked to a higher risk of lung cancer, a risk that increases with emphysema severity, according to a new study published by Yang et al in the journal Radiology. Lung cancer is the primary cause of cancer-related death worldwide. However, lung...
Topical Imiquimod vs Surgery for Vulvar High-Grade Squamous Intraepithelial Neoplasia
In an Austrian phase III trial reported in The Lancet, Trutnovsky et al found that topical imiquimod was noninferior to surgery as measured by complete clinical response in patients with vulvar high-grade squamous intraepithelial lesions. Study Details In the multicenter trial, 107 evaluable...
SBRT Plus Nivolumab With or Without Ipilimumab in Refractory Metastatic Pancreatic Cancer
In the Danish single-institution phase II CheckPAC study reported in the Journal of Clinical Oncology, Chen et al found that the combination of nivolumab and ipilimumab plus stereotactic body radiotherapy (SBRT) improved the clinical benefit rate vs nivolumab plus SBRT in patients with refractory...
SWOG-1216: Orteronel vs Bicalutamide With ADT for Metastatic Hormone-Sensitive Prostate Cancer
As reported in the Journal of Clinical Oncology by Neeraj Agarwal, MD, and colleagues, the phase III SWOG-1216 trial showed no significant improvement in overall survival—the study’s primary endpoint—with orteronel plus androgen-deprivation therapy (ADT) vs bicalutamide plus ADT in patients with...
Study Reports New Potential Target for CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy has made an impact on the treatment of certain blood cancers, but in clinical study, the cellular therapy has not been as successful for patients with solid tumors, due in part to the lack of tumor targets not expressed in vital tissues. In a new study ...
Do AYA Cancer Survivors Face a Higher Risk of Developing and Dying From a New Primary Cancer?
New findings published by Hyuna Sung, PhD, and colleagues in the Journal of the National Cancer Institute showed that 5-year survivors of adolescent and young adult (AYA) cancer in the United States have a higher risk of developing—and nearly double the risk of dying from—a new primary cancer,...
Cemiplimab-rwlc Improves Overall Survival vs Chemotherapy in Recurrent Cervical Cancer After First-Line Platinum-Based Chemotherapy
As reported in The New England Journal of Medicine by Krishnansu S. Tewari, MD, of the Division of Gynecologic Oncology, University of California, Irvine, and colleagues, the phase III EMPOWER-Cervical1/GOG-3016/ENGOT-cx9 trial has shown improved overall survival with cemiplimab-rwlc vs...
Demystifying Immunotherapy for Early-Stage Triple-Negative Breast Cancer
Immunotherapy has become a potential strategy in treating triple-negative breast cancer, though many questions remain to be answered before long-term survival is achieved by all patients. This exciting field of breast cancer research was explored at the 2022 Miami Breast Cancer Conference by...
Research Suggests Over Half of Eligible Women Would Prefer Self-Sampling for Cervical Screening
According to the results of a new study published by Drysdale et al in the Journal of Medical Screening, 51.4% of women preferred self-sampling for human papillomavirus (HPV)-based cervical cancer screening, compared to 36.5% who preferred being tested by a clinician. The findings came from a...
ASCO’s CancerLinQ® and Atropos Health Collaborate to Harness Real-World Data to Provide Point-of-Care Informatics Consult to Oncologists
ASCO’s CancerLinQ® and Atropos Health announced today a new collaboration that will provide oncology clinicians with the latest real-world evidence available to help inform personalized care and treatment of an individual patient.Atropos Health and CancerLinQ will work together to provide a...
Study Finds Long-Term Increase in Cancer Risk After High Childhood BMI
Men who had a high body mass index (BMI) as children are at an elevated risk of obesity-related cancer later in life, even if their weight was normal in young adulthood, according to a new study from researchers at the University of Gothenburg, Sweden. Célind et al published their findings in the...
Patient-Reported Outcomes and Toxicity With Adjuvant Stereotactic Pelvic Radiation Therapy in Uterine Cancers
In the Canadian phase I/II SPARTACUS study reported in JAMA Oncology, Leung et al found very low rates of severe genitourinary and gastrointestinal toxicity and worsening in only one patient-reported outcome domain among women receiving adjuvant stereotactic hypofractionated pelvic radiation...
Cancer Rates Declining in Canada, but Cases and Deaths Increasing Because of Demographic Factors
Overall cancer rates in Canada are declining, but the number of cases and deaths are increasing slightly because of population growth and an aging population, according to a new study published by Brenner et al in CMAJ (Canadian Medical Association Journal). The study is the result of a...
Addition of Ivosidenib to Azacitidine in Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia
In the phase III AGILE trial reported in The New England Journal of Medicine, Montesinos et al found that the addition of ivosidenib to azacitidine in induction therapy significantly prolonged event-free survival in patients with newly diagnosed IDH1-mutated acute myeloid leukemia. An overall...
Patients With Cancer Face Greater Risks From Abdominal Aneurysm Repair
Elective abdominal aortic aneurysm repair in patients with a cancer diagnosis is associated with several poor postoperative outcomes, according to a newly published study from researchers at the University of Missouri School of Medicine. Roush et al reported their findings in the Journal of...
Study Identifies Genetic Changes in Patients With Barrett’s Esophagus That Progresses to Esophageal Cancer
Using whole-genome sequencing to contrast genomic alterations in patients with stable Barrett’s esophagus compared to patients whose Barrett’s progressed to esophageal adenocarcinoma, Paulson et al reported that DNA changes presaging esophageal cancer can be spotted years before cancer develops....
Increased Risk of Cancer in Early Life Among Individuals With Autism Spectrum Disorders
In the largest and most detailed population-based cohort study to date, researchers from the Karolinska Institute in Stockholm found that individuals with autism spectrum disorders, when present with comorbid intellectual disability and/or birth defects, were at a higher risk of cancer in early...
Gut Microbiome May Alter Response to Cancer Therapy
Recent findings with the use of sequencing technology have suggested that the gut microbiome may play a role in the treatment of cancer. A review paper published in JAMA Oncology by Liu and Shah captured the current understanding of the connection between the gut microbiome and therapeutic response ...
Switch to Maintenance Endocrine Therapy Plus Bevacizumab After First-Line Paclitaxel/Bevacizumab Induction in Advanced Estrogen Receptor–Positive, HER2-Negative Breast Cancer
In the Japanese phase II BOOSTER trial reported in The Lancet Oncology, Saji et al found that compared with continuing paclitaxel/bevacizumab, a maintenance strategy of switching to endocrine therapy plus bevacizumab (with the option of reinitiating paclitaxel/bevacizumab) was associated with a...
Improved Long-Term Quality-of-Life Measures in Women Undergoing Breast Conservation vs Mastectomy and Reconstruction for Early Breast Cancer
In a study reported in JAMA Surgery, Hanson et al found no difference in long-term satisfaction with breasts among women with early breast cancer who underwent breast-conserving surgery with radiation therapy vs mastectomy and breast reconstruction without radiation therapy. Women who underwent...
How to Get the Dose Right
OCE Insights is an occasional column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Mirat Shah, MD, of the Office of Oncologic Diseases, Center for Drug Evaluation and Research, FDA; Atiqur...
SORAYA Trial: Mirvetuximab Soravtansine Improves Response Rate in Drug-Resistant Ovarian Cancer
The novel antibody-drug conjugate mirvetuximab soravtansine could become the new standard of care for patients with folate receptor alpha–positive, platinum-resistant ovarian cancer, according to data presented at the Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer.1...
Study Finds CAR T-Cell Therapy Outcomes, Side Effects Are Similar in Black and Hispanic Patients Compared to White and Asian Patients
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of blood cancers, including certain leukemias, lymphomas, and multiple myeloma. However, Black and Hispanic patients were largely absent from the major clinical trials that led to the U.S. Food and Drug Administration...
Preoperative Radiotherapy and DIEP Flap Reconstruction in Women Requiring Mastectomy for Breast Cancer
In the PRADA study—reported by Thiruchelvam et al in The Lancet Oncology—researchers found that a strategy of preoperative radiotherapy and deep inferior epigastric perforator (DIEP) flap reconstruction was feasible and safe in women requiring mastectomy for breast cancer. As stated by the...
Overall Survival in the ARCHES Trial: Addition of Enzalutamide to ADT for Metastatic Hormone-Sensitive Prostate Cancer
As reported in the Journal of Clinical Oncology by Andrew J. Armstrong, MD, ScM, and colleagues, the final overall survival analysis of the phase III ARCHES trial showed a significant benefit with the addition of enzalutamide to androgen-deprivation therapy (ADT) in patients with metastatic...
Updated Guidance for COVID-19 Vaccination From NCCN Recommends Fifth mRNA Shot (Second Booster Dose) for Immunocompromised People
The National Comprehensive Cancer Network® (NCCN®) has released the latest recommendations from the NCCN Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis. The updated recommendations point to two booster vaccine doses for people who are immunocompromised (meaning three...
Marcia R. Cruz-Correa, MD, PhD, on a Vision for the Future of Cancer Research and Treatment
Marcia R. Cruz-Correa, MD, PhD, of the University of Puerto Rico Comprehensive Cancer Center, discusses a way to possibly transform cancer outcomes by teaming up basic scientists, clinical researchers, and community advocates to work together, decode the complexity of cancer, and find points at...
Expert Point of View: Aditya Bardia, MD, MPH
Aditya Bardia, MD, MPH, Director of Breast Cancer Research and Attending Physician at Massachusetts General Hospital, and Associate Professor at Harvard Medical School, commented on this study on recurrence of ductal carcinoma in situ (DCIS). “This is an interesting study that evaluated whether...
Some Recurrences of Ductal Carcinoma In Situ May Be Genetically Distinct From the Primary Tumor, Study Reports
Contrary to what has been assumed, all recurrences of ductal carcinoma in situ (DCIS) are not genetically the same, according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2022.1 Almost 20% of ipsilateral recurrences found in the study were genetically...
Two Studies Examine Use of Proton-Beam Therapy in the United States
Two new, large studies led by researchers at the American Cancer Society showed an increase in the use of proton-beam therapy for patients with cancer in the United States during the past decade. However, Black patients were less likely to receive proton-beam therapy than White patients, and the...
New Study Examining Women’s Breast Density Knowledge Suggests Opportunities for Improvement
Breast density is one factor in assessing a person’s risk of developing breast cancer. Existing breast density notification laws have increased awareness among patients and providers, but clinical records had not been incorporated in studies to confirm the accuracy of personal breast density...
Navicixizumab Plus Paclitaxel in Platinum-Resistant Ovarian Cancer
In a phase Ib study reported in the Journal of Clinical Oncology, Fu et al found that the combination of navicixizumab (a bispecific antiangiogenic antibody to VEGF and delta-like ligand 4) and paclitaxel showed activity in patients with platinum-resistant ovarian cancer. Delta-like ligand 4 is a...
Assessment of Cancer Risk Profile for Germline BRCA1 and BRCA2 Pathogenic Variants in Patients With Common Cancers
In a Japanese case-control study reported in JAMA Oncology, Momozawa et al found that germline BRCA1/2 pathogenic variants were associated with an increased risk of biliary tract, esophageal, and gastric cancers, in addition to an increased risk of cancers that have well-established associations...
Narsoplimab for Hematopoietic Stem Cell Transplantation–Associated Thrombotic Microangiopathy
In a pivotal phase II trial reported in the Journal of Clinical Oncology, Samer K. Khaled, MD, and colleagues found that narsoplimab, an inhibitor of mannan-binding lectin-associated serine protease-2, showed efficacy in the treatment of adult patients with hematopoietic stem cell...
Study Examines Rates of Psychiatric Disorders and Self-Harm Among Patients Diagnosed Across 26 Cancer Types
The risk of self-harm after incident psychiatric disorder diagnosis in patients with 26 cancer types and the risk of unnatural deaths after self-harm were examined in 459,542 individuals in a study published by Chang et al in Nature Medicine. Patients with cancer may experience substantial...
Addition of High-Dose Treosulfan and Melphalan to Consolidation in High-Risk Ewing Sarcoma
In a phase III trial (Ewing 2008R3) reported in the Journal of Clinical Oncology, Koch et al found that the addition of treosulfan and melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfusion of autologous hematopoietic stem cells to consolidation did not improve event-free survival vs ...
AI May Assist Physicians in Better Assessing the Effectiveness of Bladder Cancer Treatment
In a small multi-institutional study, an artificial intelligence (AI)-based system improved providers’ assessments of whether patients with bladder cancer had complete response to chemotherapy before a radical cystectomy. These findings were published by Sun et al in Tomography. Yet the researchers ...
High-Dose Radiotherapy With Short- vs Long-Term Androgen Deprivation in Localized Prostate Cancer
As reported in The Lancet Oncology by Zapatero et al, 10-year results of the Spanish phase III DART 01/05 trial did not support the 5-year findings of significantly improved biochemical disease–free, metastasis-free, and overall survival with long-term vs short-term androgen deprivation plus...
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Carcinoma
In an interim analysis of a Chinese phase III trial (FZOCUS-2) reported in the Journal of Clinical Oncology, Li et al found that maintenance treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor fuzuloparib significantly prolonged progression-free survival vs placebo in patients with...
Maternal Malignancies May Be Identified Through Noninvasive Prenatal Test Results
In a Dutch study reported in the Journal of Clinical Oncology, Heesterbeek et al found that results of noninvasive prenatal testing for fetal aneuploidy screening using cell-free DNA derived from maternal plasma raised suspicion of maternal malignancy in a very small proportion of pregnant women....
St. Jude Receives First Group of Ukrainian Children With Cancer for Care in the United States
One month after Russia invaded Ukraine, on March 21, St. Jude Children’s Research Hospital in Memphis welcomed four Ukrainian children with cancer to be treated in the United States. Two of the children are pictured in the photos below. The four children, aged 20 months to 8 years old, traveled to...
Erratum
In the article “OlympiA Trial: Adjuvant Olaparib Significantly Improves Overall Survival in Germline BRCA-Mutated Breast Cancer,” which began on page 1 of the April 10 issue of The ASCO Post, a few unfortunate errors appeared, notably an incorrect P value for the overall survival comparison (after...
Tony Hunter, PhD, FAACR, Honored With 2022 AACR Award for Lifetime Achievement in Cancer Research
The American Association for Cancer Research (AACR) awarded the 2022 AACR Award for Lifetime Achievement in Cancer Research to Tony Hunter, PhD, FAACR, Fellow of the AACR Academy, at its Annual Meeting in New Orleans. Dr. Hunter is the American Cancer Society Professor and Renato Dulbecco Chair at ...
From Iran to Silicon Valley, a Cancer Survivor Shares Her Story
The Iranian revolution of 1979 transformed Iran from an absolute monarchy under Shah Mohammad Pahlavi to an Islamist republic under Ayatollah Khomeini. The author of a new book called The Magic of Normal, Maky Zanganeh, PhD, was born in Iran in 1970. As a young woman, she experienced the war in her ...
Immunotherapy in B-Cell Non-Hodgkin Lymphomas: Off-the-Shelf Bispecific Antibodies
Chimeric antigen receptor (CAR) T-cell therapies are a significant advance, but they require careful patient selection, dependency on patients’ own T cells, lymphodepleting chemotherapy, possible bridging therapy, manufacturing timelines with extensive health-care coordination and cost, in...
